Recent developments focus on the company’s business combination with Veraxa Biotech AG and Veraxa’s activities in oncology therapeutics.

• Voyager Acquisition Corp. entered into amendments to its Business Combination Agreement with Veraxa Biotech AG in 2025 and early 2026 to adjust terms and extend deadlines [S1][S2].
• Veraxa Biotech AG announced plans to showcase novel cancer therapies at the ASCO and BIO International Conventions in 2025 [N1].
• Veraxa Biotech AG and OmniAb, Inc. announced a co-discovery alliance for a novel bispecific antibody drug conjugate program targeting solid tumors in 2025 [N2].

The company’s business combination with Veraxa Biotech AG provides exposure to a biotechnology firm engaged in developing novel cancer therapies and bispecific antibody drug conjugates. Veraxa’s participation in major industry conventions and strategic alliances with companies like OmniAb, Inc. indicate active development and potential for innovation in oncology therapeutics. The SPAC structure allows investors to access this emerging biotech through a publicly traded vehicle.

As a SPAC, Voyager Acquisition Corp. faces risks related to the successful completion of its business combination, including regulatory approvals, shareholder votes, and market conditions. The company’s financial position shows significant current liabilities relative to assets, which may reflect obligations related to the merger process. The biotechnology sector is inherently risky, with uncertainties in clinical development, regulatory approvals, and commercialization. Failure to consummate the business combination or challenges faced by Veraxa could adversely affect the company’s prospects.

As a SPAC, Voyager Acquisition Corp. does not operate a traditional business with competitive advantages or economic moats. Its value proposition lies in its ability to complete a business combination with a target company, in this case Veraxa Biotech AG, which operates in the biotechnology sector. The moat, if any, would derive from the target company’s proprietary technologies, intellectual property, and strategic alliances in cancer therapy development, rather than from the SPAC itself.

• Business Combination Risks: The company’s ability to complete the business combination with Veraxa Biotech AG depends on regulatory approvals, shareholder approvals, and satisfaction of closing conditions. Failure to complete the combination could result in liquidation or loss of investment.
• Financial Risks: The company’s current liabilities significantly exceed current assets as of March 31, 2026, resulting in liquidity ratios of zero, which may impact its ability to meet short-term obligations without completion of the business combination.
• Biotechnology Sector Risks: Veraxa Biotech AG operates in a high-risk sector with uncertainties related to clinical trials, regulatory approvals, intellectual property protection, and market acceptance of its therapies.
• Market and Regulatory Risks: Changes in market conditions, legal and regulatory environments, and economic factors could adversely affect the company’s business combination and the operations of the combined entity.

• Voyager Acquisition Corp. is a Cayman Islands exempted company operating as a Special Purpose Acquisition Company (SPAC) with ticker VACH.
• The company has Class A ordinary shares, Class B ordinary shares, units (each consisting of one Class A ordinary share and one-half of one warrant), and warrants registered on the Nasdaq Global Market.
• As of March 10, 2026, there were 25,300,000 Class A ordinary shares and 6,325,000 Class B ordinary shares issued and outstanding.
• The company entered into a Business Combination Agreement (BCA) with Veraxa Biotech AG, a Swiss biotechnology company, with amendments to this agreement filed in 2025 and 2026.
• The company filed an amendment to its 2025 Annual Report (10-K/A) on April 2, 2026, and a quarterly report (10-Q) on May 20, 2026.
• Financial snapshot as of March 31, 2026, shows cash and cash equivalents of $6,118,000, current assets of $44,327,000, and current liabilities of $274,683,104, resulting in a current ratio and cash ratio of 0 due to the large liabilities relative to assets.
• Net income reported for the quarter ending March 31, 2026, was $180,498.
• Basic and diluted earnings per share for fiscal year 2024 were $0.26 and $0.24 respectively.
• The company is classified as a smaller reporting company and an emerging growth company, and is not a shell company.
• The aggregate market value of outstanding Class A ordinary shares as of June 30, 2025, was approximately $263 million.
• The company has entered into various agreements related to the business combination, including amendments to the Business Combination Agreement and Sponsor Support Agreement.
• Recent news relates to Veraxa Biotech AG's activities, including showcasing novel cancer therapies at ASCO and BIO International Conventions and a co-discovery alliance with OmniAb, Inc. for a bispecific antibody drug conjugate program targeting solid tumors.
• The company’s business combination with Veraxa Biotech AG involves a merger and issuance of shares and warrants to Veraxa shareholders.
• The company’s filings include disclosures about risks, including those related to the timing and structure of the business combination, regulatory approvals, shareholder approvals, and operational risks post-combination.